Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.74 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.74 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.74 |
| ▸ | PPARG | P37231 | 7/20 | 0.74 |
| ▸ | PPARD | Q03181 | 7/20 | 0.74 |
| ▸ | PPARA | Q07869 | 7/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 4/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | TLR2 | O60603 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | FABP4 | P15090 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.74 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492074 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL16012879 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| Adipic Acid SCHEMBL11453017 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL775625 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL20943305 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL25195763 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL18558704 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL16829864 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL8421567 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL10780484 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070122508-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | HELIXIR CO., LTD. (KR) | 2007-05-31 | — | — | US | claimed |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | MEDIHELPLINE CO., LTD (KR) | 2026-05-05 | — | — | US | disclosed |
| US-12606822-B2 | Synthetic modified RNA and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-21 | — | — | US | disclosed |
| US-12582617-B2 | Methods for treating cancer | RADIUS PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014153-A1 | ELACESTRANT IN COMBINATION WITH ABEMACICLIB IN WOMEN WITH BREAST CANCER | RADIUS PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250367140-A1 | METHODS FOR TREATING CANCER | RADIUS PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367141-A1 | METHODS FOR TREATING CANCER | RADIUS PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025226839-A2 | AUF1 COMPOSITIONS AND METHODS FOR PROMOTING GENERATION OF NEUROMUSCULAR JUNCTIONS | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250319044-A1 | METHODS FOR TREATING CANCER RESISTANT TO CDK4/6 INHIBITORS | RADIUS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| WO-2006048526-A2 | NON-IRRITATING RAPID-ACTION DEPILATORY COMPOSITION | PRODUCCIONES INFOVISION (MX) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006016728-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS | HELIXIR CO., LTD. (KR) | 2006-02-16 | — | — | WO | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1551433-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE | Pangenomics Co., Ltd. (KR) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004096171-A1 | SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004017982-A1 | COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE | PANGENOMICS CO., LTD (KR) | 2004-03-04 | — | — | WO | disclosed |
| US-20040037909-A1 | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | VIROMED CO., LTD. (KR) | 2004-02-26 | — | — | US | disclosed |
| US-5855826-A | Matrix-double encapsulation method and a cosmetic composition containing matrix-double capsules | PACIFIC CORPORATION (KR) | 1999-01-05 | — | — | US | disclosed |
| EP-0332501-B1 | Use of polyacrylate polymers as stabilizing agents of dispersions constituted of a water-insoluble phase in an aqueous phase, dispersions obtained, and their preparation | PAYOT N G LAB (FR) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367141-A1 | METHODS FOR TREATING CANCER | TP53, RAD1, BRCA1 | FFAR4 3933/4885FFAR1 2610/4885GPR84 1664/4885 |
| US-12606822-B2 | Synthetic modified RNA and uses thereof | CES1, MAT1A, CPS1 | FFAR4 3724/4885FFAR1 1952/4885GPR84 3292/4885 |
| US-12582617-B2 | Methods for treating cancer | BRCA1, FSHR, RAD1 | FFAR4 2964/4885FFAR1 2104/4885GPR84 4421/4885 |
| US-20250367140-A1 | METHODS FOR TREATING CANCER | TP53, RAD50, RAD1 | FFAR4 4452/4885FFAR1 4238/4885GPR84 1814/4885 |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | BRCA1, TP53, RAD1 | FFAR4 4092/4885FFAR1 3431/4885GPR84 3016/4885 |
| US-20260014153-A1 | ELACESTRANT IN COMBINATION WITH ABEMACICLIB IN WOMEN WITH BREAST CANCER | ESR1, CDK4, ERBB2 | FFAR4 1779/4885FFAR1 2886/4885GPR84 4089/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | FFAR4 3866/4885FFAR1 2425/4885GPR84 2424/4885 |
| US-20250319044-A1 | METHODS FOR TREATING CANCER RESISTANT TO CDK4/6 INHIBITORS | CDK4, ESR1, TP53 | FFAR4 3302/4885FFAR1 3579/4885GPR84 1230/4885 |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | CUTA, VEGFA, MMP8 | FFAR4 2190/4885FFAR1 1621/4885GPR84 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.